$BMY Recent Headlines

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2014 at 12:13 PM

$BMY Recent Headlines

GlaxoSmithKline exits cancer drugs
8:36 a.m. Today8:36 a.m. April 22, 2014
- MarketWatch.com

Merck: Hepatitis C drug has 98% cure rate in trial
11:43 a.m. April 10, 2014
- MarketWatch.com

Market rookie Five Prime's shares surge on deal with Bristol-Myers

12:01 p.m. March 17, 2014
- Russ Britt

RadioShack sinks; J.C. Penney gains on S&P outlook hike
5:19 p.m. March 4, 2014
- Sue Chang

Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment

5:01 p.m. March 4, 2014
- Russ Britt

Billionaire Stan Druckenmiller's recent moves
12:50 p.m. Feb. 24, 2014
- Insider Monkey

Feds, pharma rivals team up on Alzheimer's

3:32 p.m. Feb. 6, 2014
- Elizabeth O'Brien

Merck hits a new high as analyst sees opening for new cancer drug

12:16 p.m. Jan. 27, 2014
- Russ Britt

U.S. stocks tumble; Dow drops 318 points
6:29 p.m. Jan. 24, 2014
- Anora Mahmudova

Juniper buoyed by Jana stake; Herbalife loss grows
4:50 p.m. Jan. 24, 2014
- Sue Chang

U.S. stock futures trim losses ahead of market open
9:57 a.m. Jan. 24, 2014
- Barbara Kollmeyer

Beam, Honeywell, Procter & Gamble are stocks to watch
6:38 a.m. Jan. 24, 2014
- Sue Chang

AstraZeneca, Bristol-Myers Secure EU OK for Xigduo
3:44 a.m. Jan. 22, 2014
- MarketWatch.com

‘Sloppy’ market turns to consumer, tech earnings
9:01 a.m. Jan. 19, 2014
- Wallace Witkowski

America's best and most generous 401(k)s

3:30 p.m. Jan. 15, 2014
- Anne Tergesen

Merck initiates melanoma filing with FDA
12:45 p.m. Jan. 13, 2014
- Tess Stynes

Statin usefulness questioned, but patent expirations may ease pain

2:02 p.m. Jan. 8, 2014
- Russ Britt

Not all pharmaceuticals are created equal
1:40 p.m. Dec. 26, 2013
- The Trading Deck

FTSE 100 rises, shaking off retail data after Fed taper
1:06 p.m. Dec. 19, 2013
- Sara Sjolin

European stocks rally on Fed taper, rate views
1:00 p.m. Dec. 19, 2013
- Sara Sjolin

Glaxo Exits Cancer Drugs

8:19 a.m. Today8:19 a.m. April 22, 2014
- The Wall Street Journal Interactive Edition

Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff

4:23 p.m. April 21, 2014
- Seeking Alpha

AstraZeneca Shares Rise on Deal Speculation

4:08 p.m. April 21, 2014
- The Wall Street Journal Interactive Edition

Pfizer, AstraZeneca Rise On Report Of Merger Talks

10:13 a.m. April 21, 2014
- Investors Business Daily

3 Stocks Reiterated As A Buy: BMY, XOM, MET

9:59 a.m. April 21, 2014
- TheStreet.com

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside
8:39 a.m. April 21, 2014
- 247WallSt.com

3 Stocks To Capitalize On Advances In Hepatitis C Treatment

8:31 a.m. April 21, 2014
- Seeking Alpha

Big Pharma Q1 Sales Hurt by Exchange Rates

11:34 a.m. April 17, 2014
- Barrons.com

3 Stocks Reiterated As A Buy: BMY, CELG, V

9:59 a.m. April 16, 2014
- TheStreet.com

3 Pharmaceuticals to Profit on Obamacare

6:34 a.m. April 16, 2014
- InvestorPlace.com

New Drug Cocktail Should Boost AbbVie Shares

2:29 p.m. April 15, 2014
- Barrons.com

Bristol-Myers files for HIV-1 combo drug

9:04 a.m. April 14, 2014
- Seeking Alpha

Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?

8:07 a.m. April 14, 2014
- Wall St. Cheat Sheet

UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate

7:08 a.m. April 14, 2014
- benzinga.com

Cramer's Mad Money - 11 Things To Watch In The Week Ahead (4/11/14)

6:28 a.m. April 13, 2014
- Seeking Alpha

3 Stocks Reiterated As A Buy: BMY, LOW, CSCO

3:59 p.m. April 11, 2014
- TheStreet.com

Merck's Hepatitis C Drug May Boost Stock

11:09 a.m. April 11, 2014
- Barrons.com

Market Hustle: Stock Futures Sink as JPMorgan's Profit Shrinks

8:51 a.m. April 11, 2014
- TheStreet.com

Investors: Brace for a Turbulent Second Quarter

1:07 p.m. April 10, 2014
- FOXBusiness

Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients
7:05 a.m. April 10, 2014
- CNW Group

Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
11:30 a.m. April 17, 2014
- PR Newswire - PRF

FluoroPharma Appoints Dr. H. William Strauss, Internationally
Recognized Expert in the Field of Cardiovascular Nuclear Medicine, to
Chair the Scientific Advisory Board
7:27 a.m. April 14, 2014
- Marketwire

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments
10:00 a.m. April 10, 2014
- PR Newswire - PRF

Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services
8:00 a.m. April 8, 2014
- PR Newswire - PRF

Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
12:34 p.m. April 7, 2014
- PR Newswire - PRF

Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to
US FDA for the Treatment of Hepatitis C
8:03 a.m. April 7, 2014
- BusinessWire - BZX

Theravance Appoints Kevin Kwok, Head of Talent Acquisition and
Strategy
4:05 p.m. April 1, 2014
- Marketwire

Bristol-Myers Squibb to Announce Results for First Quarter 2014 on
April 29
9:00 a.m. April 1, 2014
- BusinessWire - BZX

Bristol-Myers Squibb Executive Maclean Becomes Precision Health Economics' Chief Operating Officer
10:22 a.m. March 31, 2014
- PR Newswire - PRF

INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
1:50 a.m. March 31, 2014
- GlobeNewswire

In A Subanalysis, The Benefits Of Eliquis®
(apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With
Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood
Pressure Control 1
8:16 a.m. March 27, 2014
- BusinessWire - BZX

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
4:51 p.m. March 26, 2014
- PR Newswire - PRF

Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit
12:11 p.m. March 26, 2014
- PR Newswire - PRF

Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
4:30 p.m. March 25, 2014
- GlobeNewswire

Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
8:00 a.m. March 25, 2014
- PR Newswire - PRF

Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple
Investigational All-oral Combinations across Hepatitis C Genotypes at
The International Liver CongressTM
5:39 a.m. March 24, 2014
- BusinessWire - BZX

FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx
8:00 a.m. March 21, 2014
- PR Newswire - PRF

Trace One Names Mark Martini as Vice President of North America to
Lead Sales and Customer Development
9:01 a.m. March 20, 2014
- BusinessWire - BZX

Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
8:15 a.m. March 19, 2014
- GlobeNewswire

Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
8:00 a.m. March 19, 2014
- PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Delhi Pushes Innovation Against Dryland Challenges

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Silk Road Maritime Extends Its Global Reach in 2026

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Protecting Teeth: Insights from Endodontist Dr. Joubert

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

SMPL Faces Legal Drama: What Investors Need to Know

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...